Latest Camurus News & Updates

See the latest news and media coverage for Camurus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Camurus

Swedish biopharmaceutical company developing long-acting medicines

camurus.com

Headquarters: Lund, Sweden
Founded year: 1991
Company type: Public company
Number of employees: 300–500
Industry: Pharmaceuticals

Last updated Today

Latest news about Camurus

In short: Camurus achieved record revenues and strategic milestones, including the FDA acceptance of its resubmitted NDA for acromegaly drug Oclaiz.

Company announcements

June 10 Camurus

Camurus updates on regulatory process for CAM2029 in the USA

FDA issued a request for additional information regarding the application for marketing approval for CAM2029 (Oclaiz) for acromegaly.

June 1 Camurus

Camurus announces expanded collaboration with Lilly

Lilly exercises option for amylin agonists. Camurus receives up to 870 million USD in milestone payments.

May 12 Camurus

Camurus publishes interim report for Q1 2026

Revenues decreased 5% and FDA accepted application for Oclaiz.

April 29 Camurus

Camurus announces annual report for 2025 available

The annual report is available on the website in ESEF format. During 2025, growth, increased profitability and progress in the portfolio were achieved. Sustainability report is included.

Media coverage

July 17 Endocrinology Advisor

FDA Accepts Camurus’ Resubmitted NDA for CAM2029 in Acromegaly

The FDA has accepted Camurus' resubmitted NDA for CAM2029 (octreotide) extended-release injection for acromegaly, setting a PDUFA date of December 18, 2026.

July 15 Yahoo Finance

Camurus AB (CAMX.ST) Q1 FY2026 earnings call transcript

Earnings call Camurus delivered Q1 2026 results in line with guidance: revenue of SEK 533 million rose 15% sequentially but declined 5% YoY due to...

July 14 Seeking Alpha

Camurus AB (publ) 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:CAMRF) 2026-07-15 | Seeking Alpha

2026-07-15. The following slide deck was published by Camurus AB (publ) in conjunction with their 2026 Q2 earnings call.

June 11 Reuters

Camurus' hormone disorder drug expected to be approved in 2027 after fresh FDA setback

Wall Street has pushed to next year expectations for a U.S. approval for Camurus' drug to treat a rare hormonal condition after the health ‌regulator's...

Never miss news about Camurus

Track Camurus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Camurus competitors & trending companies

Browse news for competitors to Camurus and other trending companies.